Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Topsalysin - Sophiris Bio

Next Previous
X
Search
Drug Profile

Topsalysin - Sophiris Bio

Alternative Names: PRX-302; PSA-PA 1; PSA-PAH 1

Latest Information Update: 04 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins University; University of Victoria
  • Developer Sophiris Bio
  • Class Antineoplastics; Bacterial toxins; Pore forming cytotoxic proteins; Urologics
  • Mechanism of Action Apoptosis stimulants; Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Benign prostatic hyperplasia
  • Phase II Prostate cancer

Most Recent Events

  • 04 Feb 2020 Topsalysin is still in phase II trials for Prostate cancer (In adults, In the elderly) in USA (NCT03081481)
  • 20 Jun 2019 Sophiris Bio receives positive feedback from EMA regarding planned phase III localised Prostate cancer clinical trial design
  • 25 Apr 2019 Sophiris Bio has patent protection for topsalysin in worldwide

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top